Strong Top-Line Growth
Total revenue of $1.27B in Q1 2026, up 21% year-over-year; net sales $1.10B, up 20% YoY. Reaffirmed full-year 2026 net sales guidance of $4.77B–$4.94B (up ~10%–13% vs prior year).
Incyte
· INCY
April 28th, 2026
Summary
- Earnings Call Date:
- 2026-04-28
- Change Since:
- +10.97%
- Next Earnings Date:
- 2026-08-04
Earnings Call Sentiment
PositiveThe call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.
Company Guidance
Management reaffirmed full‑year 2026 net sales guidance of $4.77–$4.94 billion (≈10–13% growth), including Jakafi sales of $3.22–$3.27 billion, Opzelura $750–$790 million and hematology/oncology products $800–$880 million; total GAAP R&D plus SG&A operating expenses are guided to $3.495–$3.675 billion, with cost of sales expected to be ~9% of net sales and a revenue mix of ~80% U.S./20% international. In Q1 they reported $1.27 billion total revenue (+21% YoY) and $1.10 billion net sales (+20%), with Jakafi at $758 million (+7%), core business ex‑Jakafi up 63%, hematology/oncology sales $204 million (+116%), GAAP R&D $516 million (+18%) and GAAP SG&A $328 million (+1%); management also highlighted product targets including Jakafi XR approval/launch mid‑2026 (XR could be 10–30% of Jakafi by 2029), Opzelura Europe launch in H2 2026, core ex‑Jakafi potential ~$3–4 billion by 2030 and I&I potentially ~1/3 of total revenue by 2030.
Core Business Ex-Jakafi Accelerating
Core business excluding Jakafi grew 63% YoY. Opzelura sales $143M (up 20% YoY; U.S. $106M up 12%; International $37M up 56%). Hematology & oncology net sales grew 116% to $204M; notable contributors: Niktimvo $55M, Monjuvi $49M (up 67% YoY), Zynyz $41M.
Pipeline and Regulatory Momentum
Multiple regulatory and development milestones: FDA accepted NDA for povorcitinib in moderate–severe HS; positive Phase III vitiligo results supporting future submission; Jakafi XR on track for potential mid‑year approval/launch; Monjuvi first-line DLBCL submissions expected H1 with approval/launch anticipated early 2027; Phase III initiation for mutant CALR antibody 989 (ET) on track midyear; KRAS G12D program (734) Phase III initiated in first-line PDAC.
Compelling Late‑Stage Clinical Data for Povorcitinib
HS 54‑week data: HiSCR50 up to 71%, HiSCR75 up to 57%, HiSCR100 up to 29%; up to 20% achieved complete clearance of draining tunnels/nodules. Vitiligo Phase III: F‑VASI ≥75% primary endpoint met in two trials (n≈456 on 30 mg dose); T‑VASI50 improvements achieved. Safety profile over 52 weeks consistent with prior studies; TEAEs of special interest 2%–3%, no new safety signals reported.
Commercial and Management Readiness
Senior leadership appointments to support growth: new CFO Suky Upadhyay; Pablo Cagnoni named President & Global Head R&D; Steven Stein as CMO and Head of Late‑stage Development; Mohamed Issa as EVP Head of U.S. Commercial. U.S. commercial operations consolidated to create launch-ready organization (targeting multiple launches in 2026–2027).
Improving Operating Leverage and Stable Cost of Sales
GAAP R&D $516M (up 18% YoY) and GAAP SG&A $328M (up 1% YoY). Ongoing operating expenses increased 14% YoY vs ongoing revenues up 19% YoY, indicating improving operating leverage. Cost of sales expected to remain ~9% of net sales.
Operator
Greetings, and welcome to the Incyte First Quarter 2026 Earnings Conference Call Webcast. [Operator Instructions] As a reminder, this conference is being recorded. [Operator Instructions] It's now my pleasure to turn the call over to Alexis Smith, Vice President, Head of Investor Relations. Please go ahead, Alexis.
Alexis Smith
Thank you. Good morning, and welcome to Incyte's First Quarter 2026 Earnings Conference Call. Before we begin, I encourage everyone to go to the Investors section of our website to find the press release, related financial tables and slides that follow today's discussion. On today's call, I'm joined by Bill, Pablo and Tom, who will deliver our prepared remarks. Steven, Dave and Mohamed will also be available for the Q&A portion of today's call. I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
I will now hand the call over to Bill.
William Meury
Thank you, Alexis, and good morning, everyone. We're off to a strong start in 2026 with net sales up 20% year-over-year, driven by strong demand across our entire portfolio. In parallel, we advanced the pipeline with key regulatory and clinical milestones. We view '26 as a year of strategic progress as we transition Incyte beyond a single cornerstone product toward a high-quality, growth-oriented portfolio across hematology, oncology and immunology. T...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free